AU724546B2 - Induction of CTLs specific for natural antigens by cross-priming immunization - Google Patents

Induction of CTLs specific for natural antigens by cross-priming immunization Download PDF

Info

Publication number
AU724546B2
AU724546B2 AU33900/97A AU3390097A AU724546B2 AU 724546 B2 AU724546 B2 AU 724546B2 AU 33900/97 A AU33900/97 A AU 33900/97A AU 3390097 A AU3390097 A AU 3390097A AU 724546 B2 AU724546 B2 AU 724546B2
Authority
AU
Australia
Prior art keywords
target antigen
artificial target
antigen
tumor cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33900/97A
Other languages
English (en)
Other versions
AU3390097A (en
Inventor
Louis D. Falo Jr.
Kenneth L. Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Pittsburgh
Original Assignee
Dana Farber Cancer Institute Inc
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Pittsburgh filed Critical Dana Farber Cancer Institute Inc
Publication of AU3390097A publication Critical patent/AU3390097A/en
Application granted granted Critical
Publication of AU724546B2 publication Critical patent/AU724546B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU33900/97A 1996-06-28 1997-06-18 Induction of CTLs specific for natural antigens by cross-priming immunization Ceased AU724546B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/675332 1996-06-28
US08/675,332 US5951975A (en) 1996-06-28 1996-06-28 Induction of CTLs specific for natural antigens by cross priming immunization
PCT/US1997/010195 WO1998000163A1 (en) 1996-06-28 1997-06-18 INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION

Publications (2)

Publication Number Publication Date
AU3390097A AU3390097A (en) 1998-01-21
AU724546B2 true AU724546B2 (en) 2000-09-28

Family

ID=24710012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33900/97A Ceased AU724546B2 (en) 1996-06-28 1997-06-18 Induction of CTLs specific for natural antigens by cross-priming immunization

Country Status (7)

Country Link
US (1) US5951975A (enExample)
EP (1) EP1007087A1 (enExample)
JP (1) JP2001524928A (enExample)
AU (1) AU724546B2 (enExample)
CA (1) CA2258840A1 (enExample)
IL (1) IL127661A (enExample)
WO (1) WO1998000163A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO1999051263A2 (en) * 1998-04-08 1999-10-14 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7342002B2 (en) * 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4302513B2 (ja) * 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2005521380A (ja) * 2001-08-31 2005-07-21 カイロン コーポレイション 抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2004100984A1 (en) * 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
WO2006085983A2 (en) * 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US11559504B2 (en) * 2017-06-02 2023-01-24 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy
TW202120122A (zh) * 2019-08-13 2021-06-01 國立研究開發法人醫藥基盤・健康・營養研究所 基於免疫記憶之新穎疾病治療及預防

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
AU2157995A (en) * 1994-03-08 1995-09-25 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
AU2157995A (en) * 1994-03-08 1995-09-25 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness

Also Published As

Publication number Publication date
JP2001524928A (ja) 2001-12-04
US5951975A (en) 1999-09-14
AU3390097A (en) 1998-01-21
EP1007087A1 (en) 2000-06-14
CA2258840A1 (en) 1998-01-08
IL127661A (en) 2001-11-25
WO1998000163A1 (en) 1998-01-08
IL127661A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
AU724546B2 (en) Induction of CTLs specific for natural antigens by cross-priming immunization
WO1998000163A9 (en) INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION
Falo Jr et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
US7118751B1 (en) DNA vaccines encoding antigen linked to a domain that binds CD40
US7670611B2 (en) Cancer immunotherapy with semi-allogeneic cells
JP2006523688A (ja) ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット
HU211299A9 (en) Induction of cytotoxic t-lymphocyte responses
WO2006083289A2 (en) Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
Sartorius et al. Vaccination with filamentous bacteriophages targeting DEC‐205 induces DC maturation and potent anti‐tumor T‐cell responses in the absence of adjuvants
AU716497B2 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
McCarthy et al. Review Anti-idiotype vaccines.
CN101072582B (zh) 作为癌症疫苗佐剂的α胸腺肽
WO1999030734A1 (en) Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
US7176186B1 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
JP2006515608A (ja) ワクチンとして使用するためのハイブリッドベクター系
JP2001501220A (ja) オンコジーン産物および外来ｍｈｃ分子を用いる癌治療
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity
Paterson Rational approaches to immune regulation
US20040110283A1 (en) Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
Ruffini et al. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma
US20090074814A1 (en) DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40
Benvenuti et al. Genetic vaccination for the immunotherapy of B-cell malignancies
Stevenson et al. DNA vaccination against cancer antigens
Laxmanan Immunogenicity and effectiveness of an idiotype-based tumor vaccine
Song DNA-based vaccination against carcinoembryonic antigen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired